Indian Immunologicals Limited

www.indimmune.com

The National Dairy Development Board (NDDB) set up Indian Immunologicals Ltd. (IIL) in 1982 with the objective of making Foot and Mouth Disease (FMD) vaccine available to farmers at an affordable price. The technology for FMD vaccine manufacture was obtained from M/s. Wellcome Foundation Limited, United Kingdom. The plant in Hyderabad today has a capacity to make 80 million trivalent doses of FMD vaccine. Following the successful introduction of Foot &Mouth Disease Vaccine-Raksha, IIL launched the tissue culture vaccine "Raksharab"​ in 1989. This was the first Indian tissue culture vaccine in the market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA

GlobeNewswire | September 28, 2023

news image

Repligen Corporation a life sciences company focused on bioprocessing technology leadership, announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technolog...

Read More

Cell and Gene Therapy

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

news image

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

news image

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More

Industrial Impact

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

news image

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More
news image

Medical

REPLIGEN ANNOUNCES AGREEMENT TO ACQUIRE FLUID MANAGEMENT INNOVATOR METENOVA

GlobeNewswire | September 28, 2023

Repligen Corporation a life sciences company focused on bioprocessing technology leadership, announced that it has entered into a definitive agreement to acquire privately-held Metenova AB (Metenova) of Mölndal, Sweden. Metenova is projected to generate revenues of $24 million to $25 million for fiscal year 2023, led by the success of its magnetic mixing and drive train technolog...

Read More
news image

Cell and Gene Therapy

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More
news image

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More
news image

Industrial Impact

ELEMENT BIOSCIENCES BECOMES THE NEWEST MEMBER OF 10X GENOMICS’ COMPATIBLE PARTNER PROGRAM (CPP) ACROSS MULTIPLE SINGLE CELL APPLICATIONS

Element Biosciences, Inc. | March 01, 2022

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us